Skip to main content
Clinical Trials/NCT06355518
NCT06355518
Not yet recruiting
Not Applicable

Pre-operative Immuno-nutrition in Patients Undergoing Radical Cystectomy for Bladder Cancer: a Multicentre, Randomised, Open-label, Parallel Group Study

Fondazione IRCCS Policlinico San Matteo di Pavia2 sites in 1 country260 target enrollmentApril 2024
ConditionsBladder Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bladder Cancer
Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Enrollment
260
Locations
2
Primary Endpoint
30-day complications
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

This study will evaluate the effect of preoperative oral immunonutrition on postoperative complications in patients undergoing radical cystectomy for bladder cancer. Patients receiving preoperative immunonutrition will be compared to controls receiving a standard high-calorie, high-protein oral nutritional supplement.

Detailed Description

Radical cystectomy with pelvic lymph node dissection and urinary reconstruction is a major surgical procedure performed for bladder cancer. The literature reports an incidence of 50-88% and 30-42% for any grade complications (Clavier-Dindo grade I-IV) and severe complications (Clavier-Dindo grade ≥III), respectively. Nutritional status prior to radical cystectomy has been shown to be a strong predictor of 90-day mortality. The term "immunonutrition" refers to the oral or enteral administration of specific substrates such as omega-3 fatty acids, arginine, and nucleotides. These substrates have been shown to upregulate the host immune response, modulate inflammatory responses and improve protein synthesis after surgery, with a favorable impact on postoperative infection rates and length of hospital stay in major abdominal surgery. Data on patients undergoing radical cystectomy are scarce, mainly due to the small sample size of the studies. However, the available evidence suggests a potential beneficial effect of this nutritional intervention in patients undergoing radical cystectomy. Several aspects remain largely unclear, including the dosage and timing of immunonutrition and the impact of preoperative malnutrition risk on the efficacy of immunonutrition. This study will evaluate the effect of 7 days of preoperative immunonutrition on postoperative complications compared to patients receiving standard high-calorie, high-protein oral nutritional supplements.

Registry
clinicaltrials.gov
Start Date
April 2024
End Date
September 2026
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Surgical indication to radical cystectomy with diagnosis of muscle invasive bladder cancer (any N, any M), BCG (Bacillus Calmette-Guerin)-unresponsive non-muscle invasive bladder cancer or extensive non-muscle invasive bladder cancer that cannot be treated with endoscopic surgery alone;
  • Willingness to participate by signing written informed consent.

Exclusion Criteria

  • Age \< 18 years;
  • Pregnant or lactating women;
  • Participation in another study with nutritional supplements within the 30 days preceding and during the present study
  • Known hypersensitivity or allergy to components of immunonutrition or standard high-calorie high-protein oral nutritional supplement;
  • Need for artificial nutrition support due to totally compromised spontaneous food intake;
  • Diarrhoea with suspected malabsorption syndrome;
  • Inability to consume oral supplements as a consequence of pre-existing disease (e.g. dysphagia) or other factors (e.g. language barrier, psychological disorders, absence of a home caregiver in dependent or elderly patients);
  • Kidney failure with need for renal replacement therapy;
  • Type 1 diabetes mellitus;
  • Type 2 diabetes mellitus requiring insulin therapy and/or inadequate glycaemic control (glycosylated haemoglobin ≥7% and/or fasting plasma glucose ≥150 mg/dL);

Outcomes

Primary Outcomes

30-day complications

Time Frame: 30 days after surgery

Percentage of patients developing at least one post-operative complication (as detailed in the study protocol: infectious, urinary, gastrointestinal, and wound-related complications)

Secondary Outcomes

  • 90-day severe complications(90 days after surgery)
  • Time to recovery of bowel function(Immediately after surgery)
  • Biochemical nutritional indexes modifications(Up to hospital discharge, assessed up to 90 days)
  • Muscular strength modifications(Up hospital discharge, assessed up to 90 days)
  • 30-day severe complications(30 days after surgery)
  • Compliance(7 days before surgery)
  • Tolerability (gastrointestinal symptoms related to nutritional supplement)(7 days before surgery)
  • Weight modifications(From preadmission visit to 90-day follow-up visit)
  • Need of blood transfusions(Immediately after surgery)
  • 30-day and 90-day infectious complications(30 and 90 days after surgery)
  • 30-day and 90-day occurrence of other medical conditions(30 and 90 days after surgery)
  • Time to postoperative mobilization(Immediately after surgery)
  • Length of stay(Immediately after surgery)
  • Readmission rate(30 and 90 days after surgery)
  • 30-day and 90-day mortality(30 and 90 days after surgery)

Study Sites (2)

Loading locations...

Similar Trials